GLOBAL MEDICAL COMMUNICATIONS - GMC
A strategic approach to Medical Communications and Medical affairs
At GMC, we are committed to our clients’ success. Our team of media experts and creatives build the buzz your brand has been looking for...Interested in learning more? Contact us.
At Global Medical Communication-GMC, Medical Communications Agency, we do what it takes to stay ahead of the game. Our dedicated, experienced team incorporates innovative ideas with differentiated, successful strategies to ensure that our clients get to the top and stay there. We aspire to be leaders in creating buzzworthy healthcare campaigns for a wide array on a global scale.
OUR STORY
Traditionally, the medical communication agencies have been developing product/disease focused content, and educating Healthcare Professionals (HCPs) to disseminate the latest scientific developments. There is an unmet need for improving patient focus for medical communications, and we at team GMC, the professionals representing medical affairs, clinical practice, and media thought to join forces, to create and disseminate truly patient-focused medical communications which could help for clinical practice decision making for improved real-world patient management.
We are aware of this challenging path, but we are sure, we will not be alone on this journey.
VISION
Be a Patient-Focused, Globally Reputable Healthcare/Medical Communications Agency to Improve Patient Care
MISSION
Deliver Multi-channel, Patient-focused Healthcare/Medical Communications Created by Global Community of Clinical Experts, Patient Organizations and Industry Experts, To Improve Real World Patient Care
OUR TEAM
SERVICES
Global Medical Communications Agency-GMC is a flexible Patient-focused Healthcare Communications Agency, which means we’ll do whatever it takes to get you noticed by all the right people. Whether through strategic targeting, multimedia placements or events, we have the tools to make our clients stand out.
Check out all our services below.
BRANDING & BRAND POSITIONING
Our concern for making sure everything is taken care of, is why we dream to be a Globally Reputable Healthcare Communications Agency. We make sure no detail is overlooked, from Content Creation to Branding/Brand Positioning to Maximize Brand Value , always with the goal of keeping the Patient and the Client at the forefront.
MEDIA COMMUNICATIONS STRATEGY FOR PHARMACEUTICAL AND HEALTH CARE CAMPAIGNS
At globalmedicalcommunications-GMC , we take pride in the personalized, high quality service we offer to all of our exceptional clients, including all kind of Media. We are laser focused on increasing brand awareness and promoting impactful stories.
EDUCATION AND TRAINING (CME) SERVICES, MEDICAL AUGMENTED REALITY FOR DOCTORS IN TRAINING, SCIENTIFIC & MEDICAL DOCUMENTARIES, 3D MEDICAL ANIMATION
Congress Abstracts/Posters Journal Publications, Congress Events, Management Healthcare Campaigns, Multi-Channel Content Medical Education for doctors , Medical Augmented Reality for Doctors and Nurses in training , 3D medical education, Patient Education
STRATEGIC, NEXT GENERATION TECHNOLOGY FOR INSIGHT AND ANALYSIS FOR MEDICAL MEETING AND PRESENTATION
We leverage a fast and flexible platform to create engagement, drive interaction and provide detailed reporting and tracking. Our clients are empowered to collect valuable feedback for medical meetings, education, sales, marketing, training and more. We combine industry expertise with powerful MeetingPulse technology for surveys, polling, voting, quizzes and materials distribution, as well as integrations with Zoom, Microsoft Teams, WebEx, PowerPoint and custom APIs. This unique technology allows us to gather real-time data from physicians and healthcare professionals, provides unmatched audience insight, and improves results.
Info contact info@globalmedicalcommunications-gmc.com
MEDICAL STRATEGY AND LIFE CYCLE MANAGEMENT OF PHARMACEUTICAL PRODUCTS
Medical Strategy would cover the mapping of patient journey,target customers mapping/segmentation, product positioning, content planning and scientific activities supporting Life Cycle Management (LCM) of pharmaceutical products from Pre-Launch to Post-Launch, to keep the productgrowing in sustainable manner.
CLINICAL CONSULTING
Therapy Area Expertise and Therapeutic area knowledge.
Clinical expertise includes the general basic skills of clinical practice as well as the experience of the individual practitioner. Our Clinical expertise encompasses and balances the patient's clinical state with new therapies, new technologies and relevant research evidence.
IN THE NEWS
Recently Featured
SCIENTIFIC BREAKTHROUGH: MINIBINDERS AS POTENTIAL THERAPEUTIC OPTIONS FOR COVID-19
M.Nargund MD
Medical Affairs Consultant
Designer picomolar miniprotein inhibitors or "minibinders" are perhaps one of the most important scientific breakthroughs for developing therapeutic options for neutralizing COVID-19 virus, & for similar viral threats in future. The concept of minibinders is based on understanding & applying rules governing how proteins twist, bend and fold into their final shape.
We all know about COVID-19 (SARS-CoV-2) viral entry in to the host cells is facilitated by binding of spikes to Angiotensin Converting Enzyme-2 (ACE-2) receptor. Small designer proteins, or minibinders bind tightly to the viral spikes to inhibit their binding & hence penetration in to the cells, & are less likely to have viral mutational escape.
Unlike injectable monoclonal antibodies, minibinders could be given in nasal/inhalational form, & would have an advantage of reaching to the lungs with potentially higher efficacy, which could be useful in hospitalized patients. Another important consideration would be a simpler process & lower cost of production of minibinders as compared to monoclonal antibodies.
DUAL ACTINGIMMUNO-ANTIBIOTICS (DAIAS) : A NEW CLASS OF ANTIBIOTICS
M.Nargund MD
Medical Affairs Consultant
On October 2020, World Health Organization (WHO) declared that Antimicrobial Resistance (AMR) is one of the top 10 global public health threats facing humanity.To combat AMR, there have been many approaches for novel drug development, beyond direct-acting traditional agents, like antibacterial vaccines, antibodies and antibody–drug conjugates; phages or phage-derived proteins and microbiota-modulating therapies; anti-virulence agents that augment other agents; potentiators that enhance and augment or transform other agents; repurposed drugs, and immunomodulators that are developed for a bacterial disease (https://www.nature.com/articles/s41579-019-0288-0).
If we have a closer look at these approaches, we observe an important role the immunomodulation could play in majority of them. Scientists have now discovered a novel target as IspH, an enzyme in a metabolic pathway that is essential for most bacteria but absent in humans, making it a potentially attractive target for drug development
(https://www.nature.com/articles/s41586-020-03074-x).
4-hydroxy-3-methylbut-2-enyl diphosphate reductase (IspH/ Iron Sulfur Protein) is an enzyme in the methyl erythritol phosphate pathway of synthesis of isoprenoids, which are needed for survival of Gram-negativebacteria, mycobacteria and apicomplexans (sporozoans). Using computational modeling, researchers selected potent inhibitors of IspH, &have demonstrated that they could bind, penetrate & kill Gram negativebacteria & also stimulate immune clearance, & hence these agents arealso called as Dual Acting Immuno-Antibiotics (DAIAs), a new class of antibiotics. DAIAs are known to stimulate a population of immune cellscalled γδ T cells, which[d2] providea general (innate-like) potent antimicrobial immune response (https://doi.org/10.1038/d41586-020-03660-z).
DAIAs have been demonstrated to kill clinical isolatesof various multi-drug resistant (MDR) bacteria including Acinetobacter, Pseudomonas, Klebsiella, Enterobacter, Vibrio, Shigella, Salmonella, Yersinia,Mycobacterium, & Bacillus, & are observed to be relatively non-toxic to mammalian cells.
Photo Credit : Nature
HEAD OFFICE-ATLANTA
Request a quote
235 East Ponce De Leon Ave Decatur, GA 30030-3452, USA
SATELLITE OFFICE-MUMBAI
601, Harmony Plaza, St. Francis Road,
Mumbai 400056, India
Invest Smartly in Biotech
Investment in Our Biotech Projects :
Are you interested in investing in AI (Artifical Intelligence) in Mechanical Ventilation for ICU patients?
An ideal solution for Intensive Care patiens is the creation of the autonomous ventilator, a device integrated with algorithms, that could monitor the patient’s response to ventilation continuously, while adjusting ventilatory parameters to provide the patient with a comfortable, optimally delivered breath based on Algorithms. This is the NEAR FUTURE and nevertheless the future of AI in ICU is indeed bright.